Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Is an out-patient 50 to 80 years old.~2. Has read, understood, signed and dated the informed consent.~3. Has indolent prostate cancer defined by:~   * Clinical Stage T1c or T2a.~  * Biopsy cores of which at least 12 reveal the presence of positive cores and the absence of cores with tumor length \> 3 mm.~  * Absence of Grade 4 cells (Gleason \<7).~  * Prostate specific antigen (PSA) levels \<10 ng/ml.~4. Has a life expectancy \> 5 years.~5. Has accepted the principle of active surveillance.~6. Is willing to participate in the study for a minimum of fifteen months.~Exclusion Criteria:~1. Has prior androgen deprivation including a 5-alpha reductase inhibitor (finasteride or dutasteride) within the last 6 months.~2. Has psychological failure related to prostate cancer therapy.~3. Has any active disorder likely to affect the conduct of the study or the patient's prognosis during the study.~4. Has a mental deficiency or any other reason that may hinder the understanding or strict application of the protocol.~5. Is under judicial protection, tutorship or curatorship.~6. Is unlikely to attend control visits.~7. Is currently enrolled in an investigational study or has participated in another investigational study within the last 3 months.~8. Has an allergy or hypersensitivity to any components of leuprorelin (Enantone LP) 11.25 mg or Casodex® 50 mg.~9. Has a medical history of severely impaired hepatic function linked to bicalutamide or a pathological cause.~10. Has testosterone level \< 0.5 ng/ml.

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Leuprorelin 11.25 mg (Type: EXPERIMENTAL): Active surveillance after a single subcutaneous injection of leuprorelin 11.25 mg and bicalutamide 50 mg, tablet, orally, once daily, to prevent flare-up for 15 days.
- Active surveillance (Type: NO_INTERVENTION): Active surveillance is close medical monitoring of prostate cancer for any changes.

Based on this trial design, predict the completion outcome and termination type (if applicable).